Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis

Annals of Neurology

Volumn 73, Issue 6, 2013, Pages 729-740

  Gandhi, Roopali ^a   Healy, Brian ^a   Gholipour, Taha ^a   Egorova, Svetlana ^a   Musallam, Alexander ^a   Hussain, Mohammad Shuja ^a   Nejad, Parham ^a   Patel, Bonny ^a   Hei, Hillary ^a   Khoury, Samia ^a   Quintana, Francisco ^a   Kivisakk, Pia ^a   Chitnis, Tanuja ^a   Weiner, Howard L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EDETIC ACID; MICRORNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICRORNAS; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 84881245624     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23880     Document Type: Article

References (59)

1. Esteller M,. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
2. Kasinski AL, Slack FJ,. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
3. Lowery AJ, Miller N, McNeill RE, Kerin MJ,. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008; 14: 360-365.
4. Junker A, Hohlfeld R, Meinl E,. The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 2011; 7: 56-59.
5. Tufekci KU, Oner MG, Genc S, Genc K,. MicroRNAs and multiple sclerosis. Autoimmune Dis 2011; 2011: 807426.
6. Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009; 132: 3342-3352.
7. Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PloS One 2009; 4: e7440.
8. Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PloS One 2010; 5: e12132.
9. De Santis G, Ferracin M, Biondani A, et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 2010; 226: 165-171.
10. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009; 10: 1252-1259.
11. Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011; 134: 3578-3589.
12. Lindberg RL, Hoffmann F, Mehling M, et al. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol 2010; 40: 888-898.
13. Fenoglio C, Cantoni C, De Riz M, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett 2011; 504: 9-12.
14. Eisele S, Krumbholz M, Fischer MT, et al. Prospects of transcript profiling for mRNAs and MicroRNAs using formalin-fixed and paraffin-embedded dissected autoptic multiple sclerosis lesions. Brain Pathol 2012; 22: 607-618.
15. Martinelli-Boneschi F, Fenoglio C, Brambilla P, et al. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett 2012; 508: 4-8.
16. Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol 2012; 144: 70-79.
17. Smith KM, Guerau-de-Arellano M, Costinean S, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 2012; 189: 1567-1576.
18. Otaegui D, Baranzini SE, Armananzas R, et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PloS One 2009; 4: e6309.
19. Junker A,. Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS Lett 2011; 585: 3738-3746.
20. Guerau-de-Arellano M, Alder H, Ozer HG, et al. miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 2012; 248: 32-39.
21. Thamilarasan M, Koczan D, Hecker M, et al. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev 2012; 11: 174-179.
22. Angerstein C, Hecker M, Paap BK, et al. Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis. Mol Neurobiol 2012; 45: 520-535.
23. Murugaiyan G, Beynon V, Mittal A, et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2011; 187: 2213-2221.
24. Ponomarev ED, Veremeyko T, Barteneva N, et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011; 17: 64-70.
25. Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012; 122: 3063-3087.
26. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
27. Ma R, Jiang T, Kang X,. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 2012; 31: 38.
28. Gupta SK, Bang C, Thum T,. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 484-488.
29. Siegel SR, Mackenzie J, Chaplin G, et al. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012; 39: 6219-6225.
30. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
31. Bustin SA,. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002; 29: 23-39.
32. Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res 2011; 717: 85-90.
33. Hosmer DW, Lemeshow S,. Applied logistic regression. 2nd ed. New York, NY: Wiley, 2000.
34. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995; 57: 289-300.
35. Mosayebi G, Ghazavi A, Ghasami K, et al. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40: 627-639.
36. Hesse D, Krakauer M, Lund H, et al. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol 2011; 18: 266-272.
37. Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010; 11: 854-861.
38. Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006; 177: 4196-4202.
39. Balashov KE, Smith DR, Khoury SJ, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 1997; 94: 599-603.
40. Karni A, Koldzic DN, Bharanidharan P, et al. IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002; 125: 134-140.
41. Vaknin-Dembinsky A, Brass SD, Gandhi R, Weiner HL,. Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. J Neuroimmunol 2008; 195: 135-139.
42. Lehmann SM, Kruger C, Park B, et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012; 15: 827-835.
43. Roush S, Slack FJ,. The let-7 family of microRNAs. Trends Cell Biol 2008; 18: 505-516.
44. Grigoryev YA, Kurian SM, Hart T, et al. MicroRNA regulation of molecular networks mapped by global microRNA, mRNA, and protein expression in activated T lymphocytes. J Immunol 2011; 187: 2233-2243.
45. Swaminathan S, Suzuki K, Seddiki N, et al. Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol 2012; 188: 6238-6246.
46. Kumar M, Ahmad T, Sharma A, et al. Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation. J Allergy Clin Immunol 2011; 128: 1077.e1-10-1085.e1-10.
47. Tsuchida A, Ohno S, Wu W, et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 2011; 102: 2264-2271.
48. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-414.
49. Fayyad-Kazan H, Rouas R, Fayyad-Kazan M, et al. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem 2012; 287: 9910-9922.
50. Hong L, Yang J, Han Y, et al. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene 2012; 507: 135-138.
51. Qi J, Qiao Y, Wang P, et al. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett 2012; 586: 1201-1207.
52. Kuipers H, Schnorfeil FM, Brocker T,. Differentially expressed microRNAs regulate plasmacytoid vs. conventional dendritic cell development. Mol Immunol 2010; 48: 333-340.
53. Allantaz F, Cheng DT, Bergauer T, et al. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PloS One 2012; 7: e29979.
54. Qiu XF, Li XX, Chen Y, et al. Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats. Asian J Androl 2012; 14: 481-486.
55. Wu H, Huang M, Cao P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther 2012; 13: 281-288.
56. Jude JA, Dileepan M, Subramanian S, et al. miR-140-3p regulation of TNF-α-induced CD38 expression in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2012; 303: L460-L468.
57. Viader A, Chang LW, Fahrner T, et al. MicroRNAs modulate Schwann cell response to nerve injury by reinforcing transcriptional silencing of dedifferentiation-related genes. J Neurosci 2011; 31: 17358-17369.
58. Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009; 14: 529-538.
59. Weiner HL, Hauser S, Kappos L, et al. SUMMIT: an International Consortium to Assess Factors that Predict Disease Progression in Multiple Sclerosis. Paper presented at: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS); October 19-22, 2011; Amsterdam, the Netherlands.